Literature DB >> 31286285

Characterization and Quantification of an Fc-FGF21 Fusion Protein in Rat Serum Using Immunoaffinity LC-MS.

Fengping Li1, Yan Weng2, Guodong Zhang3, Xiaogang Han3, Dongmei Li4, Hendrik Neubert5.   

Abstract

The fusion of an Fc moiety to a therapeutic protein is widely applied as a half-life extension strategy. However, unlike monoclonal antibodies, Fc-fusion proteins have been shown to be more susceptible to protease-mediated catabolism. The resultant catabolites may still be pharmacologically active and therefore require characterization. We combined intact protein LC-MS and digestion LC-MS/MS methods to both characterize the biotransformation of the fusion protein, Fc-FGF21, and quantify the intact molecule and its major catabolites in rat serum. The digestion LC-MS/MS assay and intact protein LC-MS assay determined that there were four major catabolites formed in vivo: one amino acid (dC1), two amino acids (dC2), or three amino acids (dC3) clipped off from the C-terminus, and a truncated fragment. By 72 h post dosing, only 66% of the intact protein remained. The digestion method was developed with a sensitivity of 20 ng/mL-10 times more sensitive than the intact protein method at 200 ng/mL. While the digestion approach proved more sensitive, the intact LC-MS method was primarily employed for understanding the biotransformation of the Fc-FGF21 fusion protein in the rat in vivo study. Graphical abstract.

Entities:  

Keywords:  Fc-FGF21; LC-MS; digestion; immunoaffinity; intact protein

Year:  2019        PMID: 31286285     DOI: 10.1208/s12248-019-0356-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

Review 1.  Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.

Authors:  Ulrike Leurs; Ulrik H Mistarz; Kasper D Rand
Journal:  Eur J Pharm Biopharm       Date:  2015-03-17       Impact factor: 5.571

2.  Strategy for the Quantitation of a Protein Conjugate via Hybrid Immunocapture-Liquid Chromatography with Sequential HRMS and SRM-Based LC-MS/MS Analyses.

Authors:  Yue Zhao; Guowen Liu; Xiling Yuan; Jinping Gan; Jon E Peterson; Jim X Shen
Journal:  Anal Chem       Date:  2017-04-21       Impact factor: 6.986

3.  New opportunities with quantification of protein therapeutics by LC-MS.

Authors:  Hendrik Neubert; Keyang Xu
Journal:  Bioanalysis       Date:  2018-07-01       Impact factor: 2.681

4.  Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS.

Authors:  Mireia Fernández Ocaña; Ian T James; Musarat Kabir; Christopher Grace; Guojun Yuan; Steven W Martin; Hendrik Neubert
Journal:  Anal Chem       Date:  2012-07-05       Impact factor: 6.986

5.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Authors:  Alexei Kharitonenkov; Victor J Wroblewski; Anja Koester; Yun-Fei Chen; Cathleen K Clutinger; Xenia T Tigno; Barbara C Hansen; Armen B Shanafelt; Garret J Etgen
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

6.  LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma.

Authors:  Peter Bults; Rainer Bischoff; Hilde Bakker; Jourik A Gietema; Nico C van de Merbel
Journal:  Anal Chem       Date:  2016-01-08       Impact factor: 6.986

7.  A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.

Authors:  Shanaka Stanislaus; Randy Hecht; Junming Yie; Todd Hager; Michael Hall; Chris Spahr; Wei Wang; Jennifer Weiszmann; Yang Li; Liying Deng; Dwight Winters; Stephen Smith; Lei Zhou; Yuesheng Li; Murielle M Véniant; Jing Xu
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

8.  Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography-High-Resolution Mass Spectrometry.

Authors:  Lijuan Kang; Raul C Camacho; Wenyu Li; Katharine D'Aquino; Seohee You; Vanessa Chuo; Naidong Weng; Wenying Jian
Journal:  Anal Chem       Date:  2017-05-08       Impact factor: 6.986

9.  Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.

Authors:  Yan Weng; Tetsuya Ishino; Annette Sievers; Saswata Talukdar; Jeffrey R Chabot; Amy Tam; Weili Duan; Kelvin Kerns; Eric Sousa; Tao He; Alison Logan; Darwin Lee; Dongmei Li; Yingjiang Zhou; Barbara Bernardo; Alison Joyce; Mania Kavosi; Denise M O'Hara; Tracey Clark; Jie Guo; Craig Giragossian; Mark Stahl; Roberto A Calle; Ron Kriz; Will Somers; Laura Lin
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

10.  Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.

Authors:  Randy Hecht; Yue-Sheng Li; Jeonghoon Sun; Ed Belouski; Michael Hall; Todd Hager; Junming Yie; Wei Wang; Dwight Winters; Stephen Smith; Chris Spahr; Lei-Ting Tam; Zhongnan Shen; Shanaka Stanislaus; Narumol Chinookoswong; Yvonne Lau; Allen Sickmier; Mark Leo Michaels; Thomas Boone; Murielle M Véniant; Jing Xu
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.